How long does a drug patent last?
Patent terms, extensions and exclusivity rules in the US and EU
Matic Broz, PhD10 min
A drug patent lasts 20 years from the date the patent application was filed, in the United States, in the European Union and across the World Trade Organization. The clock does not wait for approval. Companies file their first patents while a molecule is still in the laboratory, and drug development then takes a decade or more, so much of the term is gone before the medicine reaches a pharmacy.
Extensions and separate regulatory exclusivities give some of that time back. In the US, new drugs have averaged about 12 to 15 years on the market before the first generic arrives. The rules behind that number differ between the US and the EU, and a single medicine is usually protected by several patents with different end dates.
How long does a drug patent last?
US law sets the patent term at 20 years from the date the application was filed, or from an earlier US application it continues.[1] The patent can only be enforced once it is granted, so the years spent waiting for the patent office count against the 20. The TRIPS Agreement requires every WTO member to offer at least 20 years from filing, so Europe and most other markets start from the same baseline.[2]
Drug patents can cover the active ingredient, a formulation, a manufacturing process, a delivery device or a method of use. The earliest are often filed while a candidate is still being optimized through molecular docking, laboratory studies and clinical trials. Later patents on the same medicine carry their own filing dates and expiries, so the original compound patent is rarely the last to end.[3]
Patents are only part of the protection. Regulators also grant exclusivity periods that block or delay competing applications, and both the US and the EU offer limited extensions for time lost to regulatory review. Table 1 lists the main protections a new medicine can hold; the sections below explain how they work.
| Protection | Where | Duration | Legal basis |
|---|---|---|---|
| Patent term | US | 20 years from filing | 35 U.S.C. § 154 |
| Patent term | EU and other WTO members | At least 20 years from filing | TRIPS Agreement, Art. 33 |
| Patent term extension | US | Up to 5 years, with no more than 14 years of patent life after approval | 35 U.S.C. § 156 |
| Supplementary protection certificate (SPC) | EU | Up to 5 years after patent expiry, aimed at 15 years of protection from first authorisation | Regulation (EC) No 469/2009, Art. 13 |
| Pediatric exclusivity | US | 6 months added to the patents and exclusivities that block generics | 21 U.S.C. § 355a |
| Paediatric SPC extension | EU | 6 months added to the SPC | Regulation (EC) No 1901/2006, Art. 36 |
| New chemical entity exclusivity | US | 5 years from approval, or 4 for a generic that challenges a patent | 21 U.S.C. § 355(c)(3)(E)(ii) and (j)(5)(F)(ii) |
| New clinical investigation exclusivity | US | 3 years from approval of the change | 21 U.S.C. § 355(c)(3)(E)(iii) and (iv) |
| Orphan drug exclusivity | US | 7 years from approval | 21 U.S.C. § 360cc |
| Reference biologic exclusivity | US | 12 years from first licensure; no biosimilar application for the first 4 | 42 U.S.C. § 262(k)(7) |
| Data and market protection | EU | 8 years of data protection and 2 of market protection, plus 1 for a qualifying new indication | Directive 2001/83/EC, Art. 10(1) |
| Orphan market exclusivity | EU | 10 years, or 12 with a completed paediatric investigation plan | Regulation (EC) No 141/2000, Art. 8; Regulation (EC) No 1901/2006, Art. 37 |
Can a drug patent last longer than 20 years?
Yes, but only by a limited amount. In the US, patent term adjustment adds back days lost to certain patent office delays, and patent term extension restores part of the time an eligible drug spent in clinical testing and FDA review.[10]
The extension restores half of the testing period and all of the FDA review period that fell after the patent was granted. It cannot exceed five years, it cannot take the patent life remaining after approval beyond 14 years, and only one patent per product can be extended.[4] A drug approved with 11 years of patent life left can therefore gain at most three years, because 11 plus 3 reaches the 14-year cap.
Pediatric exclusivity works differently. A company that completes pediatric studies requested by FDA earns six months, which do not lengthen the patent itself but are added to the patent and exclusivity periods that hold back generic approval.[6][3]
The more important source of extra years is often a portfolio of later patents. A 2024 study of 10 top-selling US prescription drugs found a median of 16 active patents at FDA approval, 42 at peak density 13 years later and 77 issued in total. Patents filed after approval added a median of 7.9 years of patent protection.[11] These are blockbusters, so the figures describe the most heavily patented end of the market rather than a typical medicine.
Is FDA exclusivity the same as a patent?
No. A patent is a property right granted by the patent office, while FDA exclusivity is a statutory delay or prohibition on the approval of competing drugs. Exclusivity attaches when FDA approves a qualifying drug, and it may or may not run at the same time as the patents.[6]
A new chemical entity, meaning an active ingredient FDA has never approved before, receives five years during which no generic application can be submitted, although a generic company that challenges a listed patent may file after four.[3] Three years of exclusivity reward new clinical studies that support a change such as a new indication, orphan drugs for rare diseases receive seven years, and qualifying antibiotics and antifungals can add five years to some of these periods.[6]
Biologics such as monoclonal antibodies follow a separate law. FDA cannot approve a biosimilar until 12 years after the reference product was first licensed, and cannot accept a biosimilar application during the first four. Completing requested pediatric studies extends both periods by six months.[8]
Because exclusivity runs from approval rather than filing, it matters most for medicines that reach the market with little patent life left. A new chemical entity approved after an unusually long development still gets its five years, whatever its patents say.
How long do drug patents last in Europe?
European drug patents also run 20 years from filing. The EU extension is the supplementary protection certificate (SPC), which takes effect when the basic patent expires. Its length equals the time between the patent filing and the first EU marketing authorisation, minus five years, and it cannot exceed five years. Completing an agreed paediatric investigation plan adds six months.[5][7]
The formula has a tidy consequence. Working through the arithmetic, we find that for any medicine authorised between 5 and 10 years after its patent was filed, patent and SPC together end exactly 15 years after authorisation, the overall maximum the regulation aims for.[5] A patent filed in 2010 for a drug authorised in 2018 earns a three-year SPC, moving its expiry from 2030 to 2033. Medicines that take longer than 10 years hit the five-year cap and get less than 15.
Alongside the SPC, EU law protects the originator's trial data under the 8+2+1 rule. A generic company cannot rely on that data until eight years after the first authorisation and cannot sell its product until ten years have passed. The ten years become eleven if the originator wins approval for a new indication with significant clinical benefit within the first eight.[9] Orphan medicines receive ten years of market exclusivity, or twelve when their paediatric investigation plan is completed.[7]
These periods are about to change for new medicines. On 28 September 2026 the Council of the EU adopted the pharma package, which keeps eight years of data protection but would cut market protection to one year. Extra years would be available for medicines that meet conditions such as comparative trials, early EU filing or an unmet medical need, with total protection capped at 11 years, or 12 with a new transferable voucher for priority antibiotics.[12]
Orphan exclusivity would become 9 years, or 11 for breakthrough orphan medicines.[12] The European Parliament still has to approve the texts, with a plenary vote indicatively scheduled for 23 November 2026, and the rules take effect only after publication in the Official Journal.[13][12] Until the new rules apply, the 8+2+1 rule governs.
How long before a drug becomes generic?
There is no fixed waiting period, but studies usually place US market exclusivity, the time from brand launch to the first generic, at 12 to 15 years.[3] A 2021 study of new molecular entities that first faced generic competition from 2017 through 2019 found an average of 14.1 years, and 13.0 years for drugs with more than USD 250 million in annual sales.[14]
Hemphill and Sampat show why actual exclusivity is shorter than the patents suggest. In their sample, the last-expiring patent listed for a drug ran an average of 15.9 years past approval, yet generics arrived after 12.2. Generic companies disproportionately challenge weaker and later-expiring patents, and those challenges held effective market life steady across the decade they studied.[15][3]
A generic can receive final FDA approval once the relevant patents and exclusivities have expired, or once the generic company defeats the patents that block it.[16] A Paragraph IV application challenges a listed patent before it expires. If the patent owner sues within 45 days, FDA approval is generally postponed for 30 months unless a court resolves the case sooner, and the first qualifying applicant is generally eligible for 180 days of generic exclusivity.[17]
Legal eligibility does not guarantee a generic either. FDA keeps a list of drugs that are off-patent and off-exclusivity but still have no approved generic.[18] Even with Orange Book dates in hand, FDA says it cannot predict exactly when a generic will launch, because each application, certification, exclusivity and dispute is assessed separately.[19]
The numbers shrink at each step: 20 years from filing, about 16 years of listed patent life left at approval, and 12 to 15 years of actual exclusivity in the US. For a specific FDA-approved drug, the Orange Book is the place to start, but its dates mark the earliest possible generic entry, not a launch date.
